

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 307 914 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: **29.07.92** (51) Int. Cl.⁵: **A61K 31/70**

(21) Application number: **88115146.8**

(22) Date of filing: **15.09.88**

The file contains technical information submitted
after the application was filed and not included in
this specification

(54) **Pharmaceutical compositions containing a dideoxynucleoside.**

(30) Priority: **18.09.87 US 98255**

(43) Date of publication of application:
22.03.89 Bulletin 89/12

(45) Publication of the grant of the patent:
29.07.92 Bulletin 92/31

(64) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(56) References cited:
EP-A- 0 206 497
EP-A- 0 216 510
EP-A- 0 216 511

J. MED. CHEM., vol. 30, May 1987, American
Chemical Society, Washington, DC (US); CH-
H.KIM et al., pp. 862-866

MOLECULAR PHARMACOLOGY, vol. 32, no. 1,
July 1987, The American Society for Phar-
macology and Experimental Therapeutics;
J.BALZARINI et al., pp. 162-167

J. AM. ACAD. DERMATOL., vol. 21; pp.
1213-1217

(73) Proprietor: **F. HOFFMANN-LA ROCHE AG**
Postfach 3255
CH-4002 Basel(CH)

(72) Inventor: **Soo, Whaljen**
169 Coolidge Terrace
Wyckoff, N.J. 07481(US)

(74) Representative: **Lederer, Franz, Dr. et al**
Patentanwalt Dr. Franz Lederer Lucile-
Grahn-Strasse 22
W-8000 München 80(DE)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

The field of viral chemotherapeutics has recently developed in response to the particularly challenging problems presented with respect to the diagnosis and treatment of viral diseases. Of particular interest is the development of compounds effective against retroviruses, most particularly the HIV virus.

The effectiveness of any antiviral chemotherapeutic naturally depends on many factors including the identification of the specific virus, an understanding of its infectivity, life cycle, replication, and spread within the infected host.

Unfortunately, most of these antiviral substances which are nucleoside analogs are not specific inhibitors of only viral processes. Most of these compounds will interfere to a greater or lesser degree with normal molecular processes of the host cell resulting in toxic effects on uninfected cells.

This is particularly true with the 2',3' dideoxynucleoside analogs such as 2',3' dideoxycytidine (ddC) and the analogs thereof. ddC in particular causes peripheral neuropathy which results in tingling, numbing and pain which may require potent pain killers such as morphine when administered at the dosages which are effectively antiviral.

The instant invention comprises the discovery that extremely low dosages of dideoxynucleoside analogs exhibit no neuropathic effects yet are effective in preventing AIDS or treating subjects infected with the AIDS retrovirus.

The publication, J. Med. Chem. Vol. 30 p. 862-866 discloses that in in-vitro experiments ddC concentrations of 0.5 μ M were noncytotoxic. In the document, EP-A-0206497 dosages of from 3,0-120 mg/kg/day of 2',3' -dideoxynucleosides are recommended in the treatment of viral and retroviral infections.

The instant invention relates to the use of 2',3'-dideoxycytidine in the manufacture of a medicament to provide a dosage unit containing 2',3'-dideoxycytidine in an amount sufficient to administer to a subject from 0.001 to 0.05 mg/kg/day for the prevention or treatment of AIDS.

Particularly preferred is wherein 0.001 to 0.05 mg/kg 2',3'-dideoxycytidine is administered to a subject in one to six doses per day.

Most preferred is wherein 0.01 mg/kg 2',3'-dideoxycytidine is administered four times a day to a subject.

The compound may be administered orally, intravenously, parenterally, or mucocutaneously.

It is possible for the compounds of the present invention to be administered alone in solution. However, in the preferred embodiment, the active ingredient(s) may be used or administered in a pharmaceutical formulation. These formulations comprise at least one active ingredient (the dideoxynucleoside), together with one or more pharmaceutically acceptable carriers and/or other therapeutic agents. As included within the scope of this invention, "acceptable" is defined as being compatible with other ingredients of the formulation and not injurious to the patient or host cell. These carriers include those well known to practitioners in the art as suitable for oral, rectal, nasal, topical, buccal, sublingual, vaginal, or parenteral (including subcutaneous, intramuscular, intravenous, and intradermal) administration. Specific carriers suitable for use in the invention are further defined below.

In the present case, it will be appreciated that the compounds according to the invention may also be used in the manufacture of pharmaceuticals for the treatment or prophylaxis of viral infections.

The formulations may conveniently be presented in unit dosage form and may be prepared by and methods known in the pharmaceutical art. Such methods include the preparation of the active ingredient in a carrier which may contain additional medicinally active ingredients.

One method of oral administration of the 2',3'-dideoxycytidines of the present invention consists of dissolving an effective amount of the 2',3'-dideoxycytidine in a sodium chloride solution, preferably 0.9% sodium chloride in orange juice. The preferred method is administration of the 2',3'-dideoxynucleosides in tablet form, and may include one or more of the following: lactose (hydrous, fast flow), microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, stearic acid, and other excipients, colorants, and pharmacologically compatible carriers. Compositions for oral use may be administered to patients in fasting or non-fasting state. Examples of tables formulations are indicated in Tables 1 and 2.

Formulations of the present invention suitable for oral administration (including sustained release formulations) may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid; in an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented.

Formulations suitable for topical administration include lozenges comprising the active ingredient in a flavor, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis

such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulas containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

The administered ingredients may also be used in therapy in conjunction with other anti-viral drugs and biologicals, or in conjunction with other immune modulating therapy including bone marrow or lymphocyte transplants or medications.

A particularly preferred composition contains in one dosage unit 0.01 to 5 mg of 2',3'-dideoxycytidine.

Pharmaceutical compositions may be prepared by conventional formulation technique using the ingredients outlined below:

1. 0.01 mg Tablet	
Ingredients	mg/tablet
1. 2',3'-dideoxycytidine	0.01
2. Lactose, Anhydrous	93.99
3. Iron Oxide Yellow	0.10
4. FD&C Blue #1 Lake	0.10
5. Microcrystalline Cellulose (Avicel® PH-102)	25.00
6. Croscarmellose Sodium, Type A (Ac-Di-Sol®)	5.00
7. Magnesium Stearate	0.80
Total	125.00 mg

2. 0.05 mg Tablet	
Ingredients	mg/tablet
1. 2',3'-dideoxycytidine	0.05
2. Lactose, Anhydrous	94.00
3. Iron Oxide Black	0.15
4. Microcrystalline Cellulose (Avicel® PH-102)	25.00
5. Croscarmellose Sodium, Type A (Ac-Di-Sol®)	5.00
6. Magnesium Stearate	0.80
Total	125.00 mg

EP 0 307 914 B1

3. 0.1 mg Tablet	
Ingredients	mg/tablet
1. 2',3'-dideoxycytidine	0.10
2. Lactose, Anhydrous	149.25
3. Red Oxide #7067	0.15
4. Microcrystalline Cellulose (Avicel® PH-102)	40.00
5. Croscarmellose Sodium, Type A (Ac-Di-Sol®)	8.40
6. Magnesium Stearate	2.10
Total	200.00 mg

4. 0.5 mg Tablet	
Ingredients	mg/tablet
1. 2',3'-dideoxycytidine	0.50
2. Lactose, Anhydrous	149.00
3. Microcrystalline Cellulose (Avicel® PH-102)	40.00
4. Croscarmellose Sodium, Type A (Ac-Di-Sol®)	8.40
5. Magnesium Stearate	2.10
Total	200.00 mg

5. 1.5 mg Tablet	
Ingredients	mg/tablet
1. 2',3'-dideoxycytidine	1.50
2. Lactose, Anhydrous	148.50
3. Microcrystalline Cellulose (Avicel® PH-102)	40.00
4. Croscarmellose Sodium, Type A (Ac-Di-Sol®)	8.40
5. Magnesium Stearate	1.60
Total	200.00 mg

6. 2 mg Tablet	
Ingredients	mg/tablet
1. 2',3'-dideoxycytidine	2.00
2. Lactose, Anhydrous	147.00
3. Cosmetic Iron Oxide Yellow	0.40
4. Microcrystalline Cellulose (Avicel® PH-102)	40.00
5. Croscarmellose Sodium, Type A (Ac-Di-Sol®)	8.40
6. Magnesium Stearate	2.00
Total	200.00 mg

EP 0 307 914 B1

7. 5 mg Tablet	
Ingredients	mg/tablet
1. 2',3'-dideoxycytidine	5.00
2. Lactose, Anhydrous	144.20
3. FD&C Blue #1 Lake	0.10
4. Microcrystalline Cellulose (Avicel® PH-102)	40.00
5. Croscarmellose Sodium, Type A (Ac-Di-Sol®)	8.40
6. Magnesium Stearate	2.30
Total	200.00 mg

B. Sterile Powder for Injection

1. Lyophilized Powder, 10 mg/Vial	
Ingredients	mg/vial
1. 2',3'-dideoxycytidine	10.00
2. Mannitol	50.00
3. Hydrochloric Acid (1% v/v)	
4. Water for Injection	
Note: 1. The Hydrochloric Acid solution was used to adjust the pH of the bulk solution prior to lyophilization. 2. The Water for Injection is essentially volatilized during lyophilization.	

C. Powder for Reconstitution

1. Powder for Reconstitution, 0.02 mg/ml and 0.5 mg/ml when reconstituted

Concentration when Reconstituted: 0.02 mg/ml 0.5 mg/ml

Ingredients

1. 2',3'-dideoxycytidine	0.002	0.050
2. Potassium Sorbar	0.200	0.200
3. D&D Red #33	0.006	0.006
4. FMC Corp. Raspberry Flavor #05695	0.030	0.030
5. Citric Acid	0.050	0.050
6. Sodium Citrate	0.180	0.180
7. Lactose, Anhydrous	5.000	5.000
8. Sucrose	<u>30.000</u>	<u>30.000</u>
Total	35.468 g	35.516 g

To Reconstitute:

Distilled Water to be added	76 ml	76 ml
Final volume obtained	100 ml	100 ml
Reconstituted concentration	0.02 mg/ml	0.5 mg/ml

D. Syrup

Ingredients	0.02 mg/ml	0.5 mg/ml
	g/100 ml	
1. 2',3'-dideoxycytidine	0.002	0.05
2. Sorbitol	35.00	35.00
3. Glycerin	10.00	10.00
4. Methylparaben	0.18	0.18
5. Propylparaben	0.02	0.02
6. D&C Red #33	0.005	0.005
7. FMC Corp. Raspberry Flavor #11070	0.30 ml	0.30 ml
8. Sodium Phosphate Dibasic	0.30	0.30
9. Purified Water	qs 100.00 ml	qs 100.00 ml
Final pH	7.5	7.5

Claims

- The use of 2',3'-dideoxycytidine in the manufacture of a medicament to provide a dosage unit

containing 2',3-dideoxycytidine in an amount sufficient to administer to a subject from 0.001 to 0.05 mg/kg/day for the prevention of treatment of AIDS.

Revendications

5

1. Application de 2',3'-didésoxycytidine à la préparation d'un médicament pour fournir une unité posologique contenant de la 2',3'-didésoxycytidine en une quantité suffisante aux fins d'administration à un sujet à raison de 0,001 à 0,05 mg/kg/jour pour la prévention ou le traitement du SIDA.

10 **Patentansprüche**

1. Die Verwendung von 2',3'-Dideoxycytidin bei der Herstellung eines Medikaments zur Bereitstellung einer Dosierungseinheit mit einer für die Verabreichung von 0.001 bis 0,05 mg/kg/Tag an einen Patienten zwecks Verhütung oder Behandlung von AIDS hinreichenden Menge 2',3'-Dideoxycytidin.

15

20

25

30

35

40

45

50

55

REGISTER ENTRY FOR EP0307914

European Application No EP88115146.8 filing date 15.09.1988

Priority claimed:

18.09.1987 in United States of America - doc: 98255

Designated States BE CH DE FR GB IT LI LU NL SE AT

Title PHARMACEUTICAL COMPOSITIONS CONTAINING A DIDEOXYNUCLEOSIDE.

Applicant/Proprietor

F. HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT, CH-4002 Basel, Switzerland
[ADP No. 50482934001]

Inventor

WHAIJEN SOO, 169 Coolidge Terrace, Wyckoff, N.J. 07481, United States of
America [ADP No. 56416332001]

Classified to

A61K

Address for Service

ROCHE PRODUCTS LIMITED, Broadwater Road, Welwyn Garden City, Herts, AL7
3AY, United Kingdom [ADP No. 00001404001]

EPO Representative

DR. FRANZ LEDERER, Patentanwalt Dr. Franz Lederer Lucile Grahnstrasse 22,
D-8000 München 80, Federal Republic of Germany [ADP No. 50135904001]

Publication No EP0307914 dated 22.03.1989

Publication in English

Examination requested 15.09.1988

Patent Granted with effect from 29.07.1992 (Section 25(1)) with title
PHARMACEUTICAL COMPOSITIONS CONTAINING A DIDEOXYNUCLEOSIDE.

10.07.1989 EPO: Search report published on 09.08.1989

Entry Type 25.11 Staff ID.

Auth ID. EPT

08.08.1989 Notification from EPO of change of Applicant/Proprietor details
fromF. HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT, CH-4002 Basel,
Switzerland [ADP No. 50482934001]

to

F. HOFFMANN-LA ROCHE AG, Postfach 3255, CH-4002 Basel, Switzerland
[ADP No. 56779911001]

Entry Type 25.14 Staff ID. RD06 Auth ID. EPT

present
proprietor

REGISTER ENTRY FOR EP0307914 (Cont.)

PAGE: 2

29.06.1992 Notification from EPO of change of EPO Representative details from
DR. FRANZ LEDERER, Patentanwalt Dr. Franz Lederer Lucile
Grahnsstrasse 22, D-8000 München 80, Federal Republic of Germany
[ADP No. 50135904001]

to

DR. FRANZ LEDERER, Patentanwalt Dr. Franz Lederer
Lucile-Grahn-Strasse 22, W-8000 München 80, Federal Republic of
Germany [ADP No. 50135904001]

Entry Type 25.14 Staff ID. RD06 Auth ID. EPT

10.08.1992 ROCHE PRODUCTS LIMITED, Broadwater Road, Welwyn Garden City, Herts,
AL7 3AY, United Kingdom [ADP No. 00001404001]
registered as address for service

Entry Type 8.11 Staff ID. SW1 Auth ID. AA

**** END OF REGISTER ENTRY ****

OA80-01
EP

OPTICS - PATENTS

11/06/93 16:23:31
PAGE: 1

RENEWAL DETAILS

PUBLICATION NUMBER

EP0307914

PROPRIETOR(S)

F. HOFFMANN-LA ROCHE AG, Postfach 3255, CH-4002 Basel, Switzerland

DATE FILED

15.09.1988

DATE GRANTED

29.07.1992

DATE NEXT RENEWAL DUE

15.09.1993

DATE NOT IN FORCE

DATE OF LAST RENEWAL

11.08.1992

YEAR OF LAST RENEWAL

05

STATUS

PATENT IN FORCE